Critical role for thyroid hormone receptor β2 in the regulation of paraventricular thyrotropin-releasing hormone neurons

E. Dale Abel,1 Rexford S. Ahima,2 Mary-Ellen Boers,3 Joel K. Elmquist,3 and Fredric E. Wondisford4

1Division of Endocrinology, Metabolism and Diabetes and Program in Human Molecular Biology and Genetics, University of Utah, Salt Lake City, Utah, USA
2Division of Endocrinology, Diabetes and Metabolism, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
3Division of Endocrinology and Metabolism, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA
4Section of Endocrinology and Metabolism, Pritzker School of Medicine, The University of Chicago, Chicago, Illinois, USA

Address correspondence to: E. Dale Abel, Division of Endocrinology, Metabolism and Diabetes and Program in Human Molecular Biology and Genetics, University of Utah School of Medicine, 15 North 2030 East, Building 533, Room 3410 B, Salt Lake City, Utah 84112, USA. Phone: (801) 585-0727; Fax: (801) 585-0701; E-mail: dale.abel@hmbg.utah.edu.

Received for publication July 26, 2000, and accepted in revised form March 13, 2001.

Thyroid hormone thyroxine (T4) and tri-iodothyronine (T3) production is regulated by feedback inhibition of thyrotropin (TSH) and thyrotropin-releasing hormone (TRH) synthesis in the pituitary and hypothalamus when T3 binds to thyroid hormone receptors (TRs) interacting with the promoters of the genes for the TSH subunit and TRH. All of the TR isoforms likely participate in the negative regulation of TSH production in vivo, but the identity of the specific TR isoforms that negatively regulate TRH production are less clear. To clarify the role of the TR-β2 isoform in the regulation of TRH gene expression in the hypothalamic paraventricular nucleus, we examined preprothyrotropin-releasing hormone (prepro-TRH) expression in mice lacking the TR-β2 isoform under basal conditions, after the induction of hypothyroidism with propylthiouracil, and in response to T3 administration. Prepro-TRH expression was increased in hypothyroid wild-type mice and markedly suppressed after T3 administration. In contrast, basal TRH expression was increased in TR-β2–null mice to levels seen in hypothyroid wild-type mice and did not change significantly in response to induction of hypothyroidism or T3 treatment. However, the suppression of TRH mRNA expression in response to leptin reduction during fasting was preserved in TR-β2–null mice. Thus TR-β2 is the key TR isoform responsible for T3-mediated negative-feedback regulation by hypophysiotropic TRH neurons.


Introduction

Thyroid hormone concentrations in vivo are maintained in a narrow range by the ability of thyroid hormone to limit its own production by feedback inhibition of the synthesis of thyrotropin (TSH) by pituitary thyrotrophs (1). TSH synthesis and bioactivity is also regulated by thyrotropin-releasing hormone (TRH) originating from hypothalamic paraventricular TRH neurons (2, 3). Thyroid hormone mediates the negative regulation of the TSH subunit and TRH genes by binding to thyroid hormone receptors (TRs) that interact with thyroid hormone-responsive elements on the promoters of these genes (4–6). Three tri-iodothyronine (T3) binding isoforms of the thyroid hormone exist: TR-α1, TR-β1, and TR-β2 (7). These isoforms are all expressed within the thyrotroph (8) and the TRH neurons of the paraventricular hypothalamus (9). However, TR-β2 is the most abundant isoform in the thyrotroph (10) and potentially in the TRH neurons of the paraventricular hypothalamus (9). Indeed, the restricted expression of TR-β2 (thyrotroph, TRH neurons of the paraventricular hypothalamus, developing ear, and developing retina) contrasts with the ubiquitous expression of TR-α1 and TR-β1 isoforms (7). Thus, the expression pattern of TR-β2 suggests that this isoform may be the important mediator of negative regulation of TSH and TRH production by T3.

Transgenic and knockout animals have shed important insight into the relative roles of TR isoforms in the regulation by thyroid hormone of the hypothalamic-pituitary-thyroid (HPT) axis. Mice with targeted ablation of the TR-α locus (11) or the TR-α1 gene (12) develop minor abnormalities in thyroxine (T4) and TSH concentrations. Mice that lack both TR-β isoforms (TR-β null) develop elevated concentrations of T4 and TSH and exhibit partial suppression of TSH production after
the administration of exogenous T3 (13, 14). The partial suppression of TSH production in this model suggests that the residual TR–α1 is capable, in part, of mediating the inhibition of TSH production by T3. We have shown recently that the hormonal abnormalities observed in TR–β–null mice are largely recapitulated in mice with selective ablation of TR–β2 (15), suggesting that TR–β2 is the important mediator of T3-mediated negative regulation of the HPT axis. It is of interest that mice that lack all TR isoforms develop dramatic increases in thyroid hormone concentrations, indicating that normal expression of TR–α and TR–β are ultimately required for normal regulation of the HPT axis (16, 17). It is not clear, however, if defective negative regulation is occurring equally at the level of the thyrotroph or the TRH neuron. An important role for hypothalamic TRH production in mediating the increased thyroid hormone concentrations associated with resistance to thyroid hormone was demonstrated by our laboratory in transgenic mice with pituitary-selective expression of a mutant TR (18). These animals developed elevated levels of TSH with relatively normal concentrations of T4, which only became significantly elevated after TRH administration. In contrast, expression of this mutant in the pituitaries of TR–β–null mice recapitulated the severe thyroid hormone abnormalities observed in compound knock-out mice lacking TR–α and TR–β isoforms (19). These observations raise the possibility that TR–α and TR–β isoforms serve differential roles in the regulation of TSH and TRH gene expression in the thyrotroph and the TRH neurons of the paraventricular nucleus (PVN) respectively, and suggest that TR–β isoforms might be the important mediators of negative regulation in the hypothalamus.

To test the hypothesis that the TR–β2 isoform mediates the negative feedback regulation of TRH expression in vivo, we have analyzed the effect of targeted disruption of TR–β2 expression on the response of PVN TRH mRNA expression to hypothyroidism and T3 administration in mice. Furthermore, we determined whether TR–β2 expression is required for leptin-mediated suppression of TRH mRNA expression in the PVN during fasting (20). We found complete absence of thyroid hormone responsiveness in the TRH neurons of TR–β2–null mice, but preserved responsiveness to fasting and leptin. These data suggest that the TR–β2 isoform is the critical mediator of the negative regulation of TRH expression by thyroid hormone in vivo.

Methods

Animals. TR–β2–null mice were generated as described previously (15). Studies were performed on null mice and wild-type age-matched controls of the same strain. All aspects of animal care and experimentation performed in this study were approved by the Institutional Animal Care and Use Committee of the Beth Israel Deaconess Medical Center (Boston, Massachusetts, USA). Animals were maintained on a 12-hour light/12-hour dark schedule (light on at 6 am) and fed laboratory chow and water ad libitum. Blood was obtained for total T4 and TSH by cardiac puncture at the time of sacrifice. Experimental hypothyroidism was induced by placing mice on a low–iodine-propylthiouracil diet (low–iodine-PTU diet) (Harlan Teklad Laboratory, Madison, Wisconsin, USA) for 25 days. Hyperthyroidism was induced by daily intraperitoneal injections of T3 (1 µg/ml) in buffered HEPES for 3 weeks at doses of 0.2 µg/100 g body weight during the first week, 0.5 µg/100 g body weight during the second week, and 1.0 µg/100 g body weight during the third week. Additional experiments were performed to determine the responsiveness of TRH neurons to fasting and leptin administration (20). Wild-type and TR–β2–null mice were divided into three groups. Group 1 was maintained on normal chow. Group 2 fasted for 48 hours and received four “sham” intraperitoneal injections of 0.3 ml 0.9% saline every 12 hours (first dose given 12 hours after the beginning of the fast). Group 3 fasted for 48 hours and received four intraperitoneal injections of leptin (1 µg/g body weight) every 12 hours (first dose given 12 hours after the beginning of the fast). Blood was obtained for T4 assays at base line and after 48 hours of fasting. Mice were sacrificed at 48 hours.

Hormone assays. Total T4 levels were measured in duplicate 10-µl serum samples by a specific RIA (ImmuChem coated tube-T4 1211 RIA Kit; ICN Pharmaceuticals Inc., Costa Mesa, California, USA). TSH was measured in 25-µl serum samples in triplicate determinations by a specific mouse TSH RIA using a mouse TSH/luteinizing hormone (TSH/LH) reference preparation (AFPS51718mp), a mouse TSH anti-serum (AFP98991), and rat TSH antigen for radioiodination (NIDDK-rTSH-I-9). All reagents were obtained from A.F. Parlow (Harbor University of California at Los Angeles Medical Center, Torrance, California, USA). The standard curve was performed in hyperthyroid mouse serum, and the limit of sensitivity was less than 1.2 ng/ml. The interassay and intra-assay variations were less than 6%.

Localization and quantification of preprothyrotropin-releasing hormone mRNA by in situ hybridization histochemistry. Wild-type and TR–β2–null mice, three to four per group, were anesthetized with an intraperitoneal injection of sodium pentobarbital (50 mg/kg). They were perfused transcardially with PBS prepared with diethylpyrocarbonate–treated (DEPC-treated) water, followed by 10% neutral buffered formalin. Table 1

<table>
<thead>
<tr>
<th></th>
<th>Serum T4 and TSH concentrations</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>T4 (µg/dl)</td>
</tr>
<tr>
<td>WT</td>
<td>Basal</td>
</tr>
<tr>
<td></td>
<td>3.56 ± 0.4a</td>
</tr>
<tr>
<td>TR–β2 KO</td>
<td>6.21 ± 0.4</td>
</tr>
</tbody>
</table>

For basal samples n = 7 (WT) and n = 9 (KO); for PTU-treated samples n = 4 (WT) and n = 5 (KO). Data are means ± SEM. WT, wild-type; KO, knockout. aP < 0.001, bP < 0.01, versus similarly treated KO mice (t test).
Brains were removed, immersed in the same fixative overnight, and then cryoprotected in 20% sucrose in PBS-DEPC at 4°C. Five series of 20-µm coronal sections were cut on a table-top cryotome and mounted on Superfrost Plus glass slides (Fisher Scientific Co., Pittsburgh, Pennsylvania, USA). The protocol for in situ hybridization histochemistry has been described previously (21). Preprothyrotropin-releasing hormone (prepro-TRH) mRNA was localized using a 35S UTP-labeled complementary RNA probe synthesized from a plasmid containing the cDNA for the mouse prepro-TRH gene (kind gift of Masatomo Mori, Gunma University, Maebashi, Japan). Control sections were hybridized with a sense cRNA probe. The slides were exposed to Kodak Biomax MR film (Eastman Kodak Co., Rochester, New York, USA) for 2 days, after which they were dipped in Kodak NTB2 photographic emulsion, developed after 4 days of exposure, and counterstained with cresyl violet. Brain sections were analyzed with a Nikon E600 microscope equipped with SPOT RT digital camera and software v3.0 (SPOT Diagnostics, Sterling Heights, Michigan, USA). Digitized dark-field photomicrographs of the PVN were saved as Adobe Photoshop 4.0 files (Adobe Systems Inc., San Jose, California, USA). Film autoradiograms of the hypothalamic PVN and thalamic reticular nucleus (RT), corresponding to bregma –0.58 mm, –0.82 mm and –1.22 mm, respectively (figures 36, 38 and 41 of Franklin and Paxino; ref. 22), from three to four wild-type and three to four transgenic mice, respectively, were selected, coded, and analyzed blindly by computerized laser densitometry (Molecular Dynamics, Sunnyvale, California, USA). Integrated densities of prepro-TRH mRNA in each half of the brain were summed, and mean densities in the PVN and RT were determined in each animal.

**Statistical analysis.** Differences in hormone concentrations were assessed by the unpaired Student’s t test. The level of TRH mRNA expression (assessed by densitometry of film autoradiograms) was compared by ANOVA. Differences between treatment groups as assessed by the Fisher protected least-significant difference (PLSD) test were deemed significant if the P value was less than 0.05.

**Results**

**Hormone levels.** Table 1 shows serum T4 and TSH concentrations in TR-β2–null and control mice under basal conditions and after PTU treatment. As reported previously (15), TR-β2–null mice displayed increased basal T4 and TSH concentrations. After PTU treatment, T4 levels decreased below the level of assay detection. TSH concentrations rose in both groups of mice. However, as was demonstrated previously using I131-induced hypothyroidism (15), the rise in TSH was markedly blunted in hypothyroid TR-β2-null mice. We confirmed by Northern blot analysis that the blunted increase in TSH concentration in TR-β2–null mice was the result of impaired activation of TSHβ gene expression (Figure 1). In our earlier study we also demonstrated that administration of T3 to TR-β2–null mice, resulted in partial suppression of serum T4 concentrations and TSHβ gene expression (15). Similar results were obtained in this study (data not shown).

**Figure 1**

TSH response to PTU-induced hypothyroidism. Northern blot analysis of total RNA obtained from pooled pituitaries: n = 3 for wild-type (WT) and TR-β2–null (KO), demonstrating TSHβ mRNA responses in hypothroid WT and KO mice. Amount of RNA loaded in each lane (in micrograms) is shown.

**Figure 2**

(a–f) Representative dark-field photomicrographs showing prepro-TRH mRNA in the rostral PVN of WT (a–c) and TR-β2–null (KO) mice (d–f). Treatment conditions are as shown: basal (a and d), hypothyroid (b and e), and T3-treated (c and f). Scale bar, 300 µm.
**TRH expression.** Representative dark-field photomicrographs in rostral and caudal levels in the PVN of TR-β2-null and wild-type (WT) mice under basal conditions and after treatment with either PTU or T3 are shown in Figures 2 and 3. Densitometric analysis (Figure 4) revealed that basal prepro-TRH expression in rostral and caudal PVN regions were increased twofold (P < 0.05) in null versus wild-type mice. Prepro-TRH expression in the rostral and caudal PVN of wild-type mice were increased twofold and 2.5-fold, respectively, above basal after PTU and reduced by 75% and 65%, respectively, below basal after T3 administration (P < 0.05). In contrast, prepro-TRH gene expression in null mice was completely unresponsive to changes in ambient thyroid hormone concentrations.

**Effect of fasting and leptin administration.** To determine if the lack of TRH responsiveness was selective for T3-mediated pathways; we analyzed thyroid hormone levels and prepro-TRH gene expression in the PVN of wild-type and TR-β2-null mice after fasting and leptin administration. As shown in Figure 5a, fasting resulted in suppression of T4 to levels that were below the limit of detection of the T4 assay in wild-type and null mice. In leptin-treated animals the degree of T4 suppression was blunted. However, T4 concentrations in leptin-treated TR-β2-null mice remained significantly higher than levels in leptin-treated wild-type mice. Importantly, analysis of TRH expression (Figure 5b and Figure 6) demonstrated a significant reduction in TRH gene expression with fasting, which was reversed after leptin administration. Leptin regulation of TRH expression was observed in wild-type and TR-β2-null mice. However TRH expression remained higher in TR-β2-null mice than wild-type under equivalent treatment conditions.

**Discussion**

This study demonstrates, we believe for the first time, that the TR-β2 isoform is the key mediator of negative regulation in the T3-responsive neurons of the PVN. We have shown previously that TR-β1 and TR-α expression are normal in TR-β2 knockout mice (15). Thus, in contrast to the thyrotrroph where the remaining isoforms partially mediate negative regulation, in the hypothalamus this is not the case. These data therefore suggest that important differences between the thyrotrroph and the PVN exist in terms of the roles of TR isoforms in mediating negative regulation in vivo.

Basal T4 and TSH concentrations are increased in TR-β2 knockout mice, consistent with central resistance to thyroid hormone (RTH). Our previous data obtained in mice with pituitary-selective expression of a mutant TR-β suggested that increased production of both TSH and TRH at ambient levels of thyroid hor-
Thyroid hormone and TRH responses to fasting and leptin administration. (a) Fed and fasting T_4 concentrations in WT (black and red symbols) and TR-β2-null (KO) mice (green and blue symbols). n = 4 for all groups, except for saline-treated KO mice (n = 3). Data are mean ± SEM. Ap < 0.05 versus fed WT; Bp < 0.05 versus all other fasted mice by ANOVA. (b) Relative prepro-TRH expression as assessed by laser densitometry in the rostral PVN of WT (open bars) and TR-β2 KO mice (filled bars) at base line and after a 48-hour fast with and without leptin administration. Data shown are mean ± SEM. Each point represents analysis of anatomically identical sections. n = 3 fed groups, n = 3 fasted KO, n = 4 all other groups. Ap < 0.05 versus fed or fasted plus leptin groups of same genotype, respectively. Bp < 0.05 versus WT in the same treatment group by ANOVA.
tion of TSH-β gene expression were significantly greater than that observed for TRH. It is possible that this apparent discrepancy could result from limitations in our ability to quantify elevated TRH expression above certain levels by in situ hybridization histochemistry. However, these data raise additional possibilities regarding differences in the ligand-independent activation of the TSH subunit genes and the TRH gene in vivo. In wild-type mice hypothyroidism increased TSH expression more than 100-fold above base line whereas TRH expression was increased twofold to threefold, suggesting that TSH subunit genes (in vivo), are subject to greater ligand-independent activation in the absence of T₃ than is the TRH gene. In TR-β₂-null mice, hypothyroidism increased TSH-β expression by twofold to threefold, and TRH expression did not change. These observations suggest that residual TRs in the thyrotroph are able to mediate to a limited degree ligand-independent activation of the TSH-β gene in the thyrotroph, but underscore the quantitatively important role of TR-β₂ in this process. In the T₃-responsive neurons of the PVN, ligand-independent activation of TRH gene expression is completely absent in TR-β₂-null mice. This observation further supports our conclusion that TR-β₂ is the critical regulator of thyroid hormone action in the hypothalamus. The molecular mechanisms governing ligand-independent activation of these genes are partially understood, but are believed to involve the interaction of TRs with coactivator or corepressor molecules (23, 24). It will therefore be important in future studies to determine whether differences in the relative expression of known TR interacting proteins exist in the thyrotroph versus TRH neurons and to determine if such differences can account for the differences in ligand-independent activation of these genes in vivo.

Fasting leads to reduced activity of the HPT axis (25). The basis for this is decreased expression and synthesis of TRH (20). Recent data have revealed that a fall in leptin plays a central role in this phenomenon (20, 25) by its stimulatory effect on neurons in the arcuate nucleus which project to the PVN (26), and by directly activating the TRH promoter by STAT3 phosphorylation (27). Leptin-mediated regulation of TRH gene expression is, in part, independent of the regulation of TRH expression by thyroid hormone. Thus we examined the regulation of TRH gene expression by leptin in TR-β₂-null mice to determine if the defective T₃-mediated regulation was specific for TR-regulated pathways or was more generalized. TRH expression was modulated by fasting and leptin administration to equivalent degrees in wild-type and TR-β₂-null mice. However, at all points, null mice continued to exhibit greater TRH expression than wild-type controls. Thus responsiveness of TRH neurons to leptin is preserved in the absence of TR-β₂, whose major effect is in regulating the set point of TRH expression. These observations provide additional evidence for the multiple levels at which TRH expression is regulated in vivo, and strengthens our conclusions regarding the specific role of the TR-β₂ isoform in the regulation of TRH expression by thyroid hormone.

In conclusion, these studies define the essential and specific role of the TR-β₂ isoform in the regulation of TRH gene expression by thyroid hormone and define important differences between the thyrotroph and the TRH neurons in terms of TR isoform-mediated negative regulation.

Acknowledgments

We would like to thank Joseph Kelly, Charlotte Lee, and Dionne Rudder for technical assistance, and Anthony Hollenberg for helpful suggestions. The work was supported by the NIH grants DK-02485 to E.D. Abel and DK-49126 and DK-50564 to F.E. Wondisford. E.D. Abel was a recipient of a Faculty Development Award from the Robert Wood Johnson Foundation, the Eleanor and Miles Shore 50th Anniversary Scholars in Medicine Fellowship–Harvard Medical School, and a Thyroid Research Advisory Council Award.

18. Abel, E.D., et al. 1999. Novel insight from transgenic mice into thyroid hor-
19. Abel, E.D., et al. 1998. Pituitary expression of a mutant thyroid hormone receptor in TRβ K/O mice results in marked elevations of thyroid hormone concentrations. Thyroid. 8(Suppl.):P110. (Abstr.)